Energenesis Biomedical Co (6657.TW) Stock Price

Energenesis Biomedical Co Price

CLOSED
29.65
​
Market closed

Over the last 10 years Energenesis Biomedical Co grew revenue by 12.5% annually, reaching 7.67 M TWD. For Energenesis Biomedical Co, the net margin of -3,367.2% is down versus -1,605.5% a few years ago.

Energenesis Biomedical Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Energenesis Biomedical Co business model & stock analysis

Energenesis Biomedical Co., Ltd. develops new drugs, focusing on experimental service analysis and reagent sales as its main products. The company's primary new drugs include ENERGI-F703 for diabetic foot ulcers, ENERGI-F701 for abnormal alopecia, ENERGI-F711 for burns, and ENERGI-F706 for cachexia. These products target medical professionals and healthcare institutions seeking innovative treatments for specific conditions. The firm generates revenue through the sale of experimental services and reagents, as well as the commercialization of its drug pipeline. Energenesis Biomedical's product portfolio is centered around four key drug candidates, each addressing distinct medical needs. ENERGI-F703 addresses diabetic foot ulcers, a common complication in diabetes management, while ENERGI-F701 targets abnormal alopecia, a condition affecting hair growth. ENERGI-F711 is designed for burn treatment, and ENERGI-F706 focuses on cachexia, a wasting syndrome often associated with chronic diseases. These drugs are developed for direct sales to healthcare providers and institutions. The company's revenue streams are derived from two main areas: the sale of experimental service analysis and reagent products, alongside the future commercialization of its drug candidates. Healthcare institutions and medical professionals are the primary buyers of these products, seeking advanced solutions for diabetic foot ulcers, alopecia, burns, and cachexia. Energenesis Biomedical's business model relies on the successful development and market entry of its drug pipeline to generate sustained revenue.

Frequently asked questions about Energenesis Biomedical Co

9 analysts currently rate the Energenesis Biomedical Co stock: 0 recommend buying, 3 holding and 6 selling. For 2026, analysts expect Energenesis Biomedical Co to generate revenue of 8.16 M TWD and earnings per share of -2.45 TWD.

Converted at the current exchange rate, the Energenesis Biomedical Co share trades at 0.81 EUR (29.65 TWD).

The expected revenue of Energenesis Biomedical Co is 8.16 M TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Energenesis Biomedical Co is -217.41 M TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Energenesis Biomedical Co is currently -12.12. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Energenesis Biomedical Co stock.

The price-to-sales ratio (P/S) of Energenesis Biomedical Co is currently 322.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Energenesis Biomedical Co stock.

The Eulerpool Quality Score for Energenesis Biomedical Co is 4/10.

The ISIN of Energenesis Biomedical Co is TW0006657000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Energenesis Biomedical Co is 6657.TW. The ticker symbol is used to trade Energenesis Biomedical Co shares on the stock exchange.

Fair ValueTerminal
26.98 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Aug 8, 2018
ISIN
TW0006657000
Cusip
Y228BN107
Market capitalization
2.63 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-12.12
P/Se
322.95
EV/EBIT
—
P/B Ratio
2.94
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-28.65 %
Last updated Nov 11, 2026, 5:01 AM

Energenesis Biomedical Co Peer Group

Energenesis Biomedical Co FIGI

6657:TT (Taiwan Stock Exchange) · BBG00LLVJY15